| Identification | Back Directory | [Name]
Gemcitabine-13C,15N2 (hydrochloride) | [CAS]
2757566-59-7 | [Synonyms]
2'-deoxy-2',2'-difluoro-cytidine-2-13C-1,3-15N2,monohydrochloride | [Molecular Formula]
C9H11F2N3O4.ClH | [MOL File]
2757566-59-7.mol | [Molecular Weight]
302.64 |
| Hazard Information | Back Directory | [Uses]
Gemcitabine-13C,15N2 (hydrochloride) is the 13C and 15N labeled Gemcitabine hydrochloride[1]. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[2][3]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80 PMID:21965724
[3] Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer18(2):198-206 DOI:10.1089/jam.2005.18.198
[4] Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2292(22):9136-9149. DOI:10.1074/jbc.M117.783365
[5] Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 1713:194. DOI:10.1186/1471-2407-13-194 |
|
|